Alcohol consumption, cigarette smoking, and risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Results from the BRCA1 and BRCA2 cohort consortium

Grants

Funding Acknowledgements

The Breast Cancer Family Registry (BCFR), and authorsMary Beth Terry, Irene Andrulis, David Goldgar, Saundra Buys, Esther John, and Mary Daly, were supported by grant UM1CA164920 from the NCI. This work was partially supported by the Spanish Ministry of Economy and Competitiveness (MINECO) SAF2014-57680-R and the Spanish Research Network on Rare diseases (CIBERER). This work was supported by the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program (grant no. CRN-87521) and the Ministry of Economic Development, Innovation and Export Trade (grant no. PSR-SIIRI-701). The DKFZ study was supported by the German Cancer Research Center (DKFZ). EMBRACE and D.F. Easton are supported by Cancer Research UK grants C1287/A10118 and C1287/A11990. D. Gareth Evans is supported by an NIHR grant to the Biomedical Research Centre, Manchester (IS-BRC-1215-20007). The Investigators at The Institute of Cancer Research and The RoyalMarsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. A.C. Antoniou is funded by Cancer Research UK grants C12292/A20861 and C12292/A11174. The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant no. 110837, to R.K. Schmutzler). This work was supported by LIFE -Leipzig Research Center for Civilization Diseases, Universit_at Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund (ERDF), and by means of the Free State of Saxony within the framework of the excellence initiative. The national French cohort, GENEPSO, was supported by a grant from the Fondation de France and the Ligue Nationale Contre le Cancer and is being supported by a grant from INCa as part of the European program ERA-NET on Translational Cancer Research (TRANSCAN-JTC2012, no. 2014-008). Hospital Clinico San Carlos (HCSC) was supported by a grant RD12/0036/0006 and 15/00059 from ISCIII (Spain) and partially supported by European Regional Development FEDER funds. The HEBON study is supported by the Dutch Cancer Society grants NKI19981854, NKI2004-3088, NKI2007-3756, the Netherlands Organisation of Scientific Research grant NWO 91109024, the Pink Ribbon grants 110005 and 2014-187. WO76, the BBMRI grant NWO 184.021.007/CP46, and the Transcan grant JTC 2012 Cancer 12-054. The International Hereditary Cancer Centre (IHCC) was supported by grant PBZ_KBN_122/P05/2004 and The National Centre for Research and Development (NCBR) within the framework of the international ERA-NET TRANSAN JTC 2012 application no. Cancer 12-054 (contract no. ERANET-TRANSCAN/07/2014). This work was also supported by grants to kConFab and the kConFab Follow-Up Study from Cancer Australia (809195, 1100868), the Australian National Breast Cancer Foundation (IF 17), the National Health and Medical Research Council (454508, 288704, 145684), the NIH (1RO1CA159868), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. K.-A. Phillips is an Australian National Breast Cancer Foundation fellow. L. Foretova was supported by MHCZ - DRO (MMCI, 00209805) and by MEYS -NPS I - LO1413 (to L. Foretova, M. Navratilova). E. Olah and The Hungarian Breast and Ovarian Cancer Study were supported by Hungarian Research Grants KTIAOTKA CK-80745, NKFI OTKA K-112228, and the Norwegian EEA Financial Mechanism HU0115/NA/2008-3/_OP-9. H. Olsson and Lund-BRCA collaborators are supported by the Swedish Cancer Society, Lund Hospital Funds, and European Research Council Advanced Grant ERC-2011-294576. Stockholm-BRCA collaborators are supported by the Swedish Cancer Society. BCFR wishes to thank members and participants in the Breast Cancer Family Registry from the New York, Northern California, Ontario, Philadelphia, and Utah sites for their contributions to the study. BCFR-Australia wish to acknowledge Maggie Angelakos, Judi Maskiell, Gillian Dite, and Helen Tsimiklis. CNIO thanks Alicia Barroso, Rosario Alonso, and Guillermo Pita for their assistance. We acknowledge the GENEPSO Centers (the Coordinating Center: Institut Paoli-Calmettes, Marseille, France: Catherine Nogues, Lilian Laborde, Pauline Pontois, Emanuelle Breysse, Margot Berline) and the Collaborating Centers (Institut Curie, Paris, France: Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Chrystelle Colas; Institut Gustave Roussy, Villejuif, France: Olivier Caron; Hopital Rene Huguenin/Institut Curie, Saint Cloud: Catherine Nogues, Emmanuelle MouretFourme, Claire Saule, Chrystelle Colas; Centre Paul Strauss, Strasbourg, France: Jean-Pierre Fricker; Centre Leon Berard, Lyon, France: Christine Lasset, Valerie Bonadona, Sophie Dussard; Centre Francois Baclesse, Caen, France: Pascaline Berthet; Hopital d'Enfants CHU Dijon - Centre Georges Francois Leclerc, Dijon, France: Laurence Faivre; Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France: Elisabeth Luporsi; Centre Antoine Lacassagne, Nice, France: Veronique Mari; Institut Claudius Regaud, Toulouse, France: Laurence Gladieff; Reseau Oncogenetique Poitou Charente, Niort: Paul Gesta, Stephanie Chieze-Valero; Institut PaoliCalmettes, Marseille, France: Catherine Nogues, Jessica Moretta Hagay Sobol, Francois Eisinger, Cornel Popovici; Institut Bergonie, Bordeaux, France: Michel Longy; Centre Eugene Marquis, Rennes: Louise Grivelli; GH Pitie Salpetriere, Paris, France: Chrystelle Colas, Florent Soubrier, Patrick Benusiglio; CHU Arnaud de Villeneuve, Montpellier, France: Isabelle Coupier, Pascal Pujol, Carole Corsini; Centres Paul Papin/ICO, Angers: Marie-Emmanuelle Morin-Meschin; Clinique Catherine de Sienne, Nantes, France: Alain Lortholary; Centre Oscar Lambret, Lille, France: Claude Adenis, Audrey Maillez; Institut Jean Godinot, Reims, France: Tan Dat Nguyen; Centre Rene Gauducheau, Nantes, France: Capucine Delnatte, Caroline Abadie; Centre Henri Becquerel, Rouen, France: Julie Tinat, Isabelle Tennevet; Hopital Civil, Strasbourg, France: Christine Maugard; Centre Jean Perrin, Clermont-Ferrand, France: Yves-Jean Bignon, Mathilde Gay Bellile; Polyclinique Courlancy, Reims, France: Clotilde Penet; Clinique Sainte Catherine, Avignon, France: Hel~ene Dreyfus; H<^>opital Saint-Louis, Paris, France: Odile Cohen-Haguenauer; CHRU Dupuytren, Limoges, France: Brigitte Gilbert, Laurence Venat-Bouvet; CHU de Grenoble: Dominique Leroux, Clementine Legrand, Helene Dreyfus; Hopital de la Timone, Marseille, France: Helene Zattara-Cannoni; Hopital Jacques Monod, le Havre, France: Valerie Layet, Elodie Lacaze; CHU Chambery, Chambery, France: Sandra Fert-Ferrer; Hopital Clarac, Fort de France: Odile Bera; CHU la Miletrie, Poitiers, France: Brigitte Gilbert-Dussardier, David Tougeron, Stephanie Chieze-Valero; Hopital Saint Louis, la Rochelle, France: Hakima Lallaoui; CH Pellegrin, Bordeaux, France: Julie Tinat). HCSC acknowledges Alicia Tosar and Paula Diaque for their technical assistance. The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) consists of the following Collaborating Centers: Netherlands Cancer Institute (coordinating center), Amsterdam, the Netherlands: M.A. Rookus, F.B.L. Hogervorst, F.E. van Leeuwen, M.A. Adank, M.K. Schmidt, N.S. Russell, J.L. de Lange, R. Wijnands, D.J. Jenner; Erasmus Medical Center, Rotterdam, the Netherlands: J.M. Collee, A.M.W. van den Ouweland, M.J. Hooning, C. Seynaeve, C.H.M. van Deurzen, I.M. Obdeijn; Leiden University Medical Center, Leiden, the Netherlands: C.J. van Asperen, J.T. Wijnen, R.A.E.M. Tollenaar, P. Devilee, T.C.T.E.F. van Cronenburg; Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands: C.M. Kets, A.R. Mensenkamp; University Medical Center Utrecht, Utrecht, the Netherlands: M.G.E.M. Ausems, R.B. van der Luijt, C.C. van der Pol; Amsterdam Medical Center, Amsterdam, the Netherlands: C. M. Aalfs, H.E.J. Meijers-Heijboer, T.A. M. van Os; VU University Medical Center, Amsterdam, the Netherlands: K. van Engelen, J.J.P. Gille, Q. Waisfisz; Maastricht University Medical Center, Maastricht, the Netherlands: E.B. Gomez-Garcia, M.J. Blok; University of Groningen, Groningen, the Netherlands: J. C. Oosterwijk, A.H. van der Hout, M.J. Mourits, G.H. de Bock; The Netherlands Comprehensive Cancer Organisation (IKNL): S. Siesling, J.Verloop; the nationwide network and registry of histo-and cytopathology in the Netherlands (PALGA): L.I.H. Overbeek. HEBON thanks the study participants and the registration teams of IKNL and PALGA for part of the data collection. INHERIT would like to thank Dr. Martine Dumont for sample management and skillful assistance. We thank Stephanie Nesci, Sandra Picken, Lucy Stanhope, Sarah O'Connor, Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Australian and New Zealand Family Cancer Clinics, and the many families who contribute to kConFab for their contributions to this resource. MMCI, Brno, Czech Republic -many thanks to Dita Hanouskova, research nurse, Jitka Berkovcova, research technician, for data collection and management. We wish to thank the Hungarian Breast and Ovarian Cancer Study Group members (Maria Balogh, Janos Papp, Matrai Zoltan, Judit Franko Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary) and the clinicians and patients for their contributions to this study. Swedish scientists participating as SWE-BRCA collaborators are from Lund University and University Hospital (Lund, Sweden): Hakan Olsson, Carolina Ellberg; and from Stockholm and Karolinska University Hospital (Stockholm, Sweden): Brita Arver.